Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Completed · Phase 1/Phase 2
Conditions studied: Colorectal Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of colorectal cancer. Combining chemotherapy with gefitinib may kill more tumor cells. PURPOSE: Phase I/II trial to compare the effectiveness of chemotherapy with or without gefitinib in treating patients who have metastatic or locally recurrent colorectal cancer.
Key facts
- Study ID
- NCT00026299
- Run by
- University of Chicago
- People needed
- 14
- Starts
- 2001-09-01
- Expected to finish
- 2005-02-01
- Last updated by the study team
- 2013-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Decatur Memorial Hospital Cancer Care Institute — Decatur, Illinois, United States
- Evanston Northwestern Health Care — Evanston, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- LaGrange Memorial Hospital — LaGrange, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Memorial Hospital of South Bend — South Bend, Indiana, United States
- Oncology Care Associates, P.L.L.C. — Saint Joseph, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.